Highlight
– In children (age 1–17) with newly diagnosed, favorable-prognosis B-lineage ALL (ETV6::RUNX1 positive or rapid early response), omission of two daunorubicin doses during induction did not compromise 5‑year event‑free survival (EFS) or overall survival (OS).
– Five-year EFS was 92.5% with standard additional daunorubicin (control) versus 92.2% with omission (experimental); OS was 97.6% versus 97.4%.
– The experimental arm experienced a significantly lower rate of invasive fungal infections (0.5% vs 1.5%, P = .02), while rates of life‑threatening and fatal adverse reactions were otherwise similar.
Background: clinical context and unmet need
Contemporary multiagent regimens have produced excellent cure rates for childhood acute lymphoblastic leukemia (ALL), with long-term survival often exceeding 90% for many standard-risk groups. However, anthracyclines such as daunorubicin remain a double-edged sword: important for antileukemic efficacy but implicated in both acute hematologic toxicity and progressive, dose‑dependent cardiomyopathy that can appear years to decades after therapy. Minimizing long-term morbidity while preserving high cure rates is a central objective in pediatric oncology. The AIEOP-BFM ALL 2009 randomized substudy addressed a practical question: can selected children with favorable B-lineage ALL safely receive fewer anthracycline exposures during induction without worsening short-term or intermediate oncologic outcomes?
Study design and methods
The AIEOP-BFM ALL 2009 trial is a large, international cooperative-group trial. From the overall cohort (n = 6,136), investigators identified children aged 1–17 years with newly diagnosed non–high‑risk B‑lineage ALL who had favorable biological or early-response features: either ETV6::RUNX1 fusion or a rapid treatment response assessed at induction day 15. All eligible patients began a 2‑week induction that included two once‑weekly doses of daunorubicin (30 mg/m2 each) as part of a four‑drug induction backbone. After that initial 2‑week period, patients were randomized to one of two induction strategies:
- Control arm (CA): two additional doses of daunorubicin during induction (standard exposure).
- Experimental arm (EA): omission of the two additional daunorubicin doses during induction.
The primary analysis tested noninferiority for event‑free survival (EFS) in the population of patients treated per random assignment. Safety analyses for adverse reactions of special interest (ARSIs) were performed in the as‑treated population. Trial registration: ClinicalTrials.gov NCT01117441.
Key findings
Population and randomization
Of 6,136 enrolled patients in the parent trial, 2,514 (41.0%) met eligibility for this randomization, reflecting the sizable proportion of children with favorable prognostic markers. Among these, 82.7% were actually randomized: 1,040 to the experimental arm and 1,039 to the control arm.
Primary oncologic outcomes
At 5 years the EFS was essentially identical between groups: 92.5% (standard error [SE] 0.8%) in the control arm versus 92.2% (SE 0.9%) in the experimental arm. Reported overall survival was 97.6% (SE 0.5%) versus 97.4% (SE 0.5%), respectively. Cumulative incidence of relapse at 5 years was also comparable: 5.8% (SE 0.7%) in the control arm and 5.7% (SE 0.7%) in the experimental arm. These results met the trial’s noninferiority objective, indicating that omission of the two late induction daunorubicin doses did not compromise intermediate oncologic outcomes in this preselected favorable cohort.
Safety and adverse events
Overall rates of life‑threatening and fatal adverse reactions of special interest were similar between arms, indicating no signal of increased severe toxicity related to the omission. Of note, invasive fungal infections were significantly less frequent in the experimental arm: 0.5% versus 1.5% in the control arm (P = .02), an approximately threefold relative reduction. This finding suggests that even small reductions in anthracycline exposure during induction can translate into clinically meaningful differences in infectious complications. The trial reported other safety parameters without major imbalances.
Statistical considerations and precision
The large size of the parent trial and the substantial number of randomized favorable‑risk patients provided adequate power to evaluate noninferiority for EFS. The reported standard errors allow approximation of 95% confidence intervals around the observed 5‑year EFS estimates (for example, 92.5% ± ~1.6% in the control arm), supporting the conclusion that true differences, if present, are small and clinically unlikely to favor routine additional daunorubicin in this subgroup.
Expert commentary and interpretation
These results are clinically important and pragmatic. They show that in a well‑defined subset of pediatric B‑cell ALL—children with either ETV6::RUNX1 fusion or rapid early response—eliminating two doses of daunorubicin in the latter part of induction preserves excellent medium‑term leukemia control while reducing at least one form of acute infectious toxicity.
Biological plausibility: anthracyclines contribute to marrow suppression and cumulative immunosuppression, which can predispose to opportunistic infections, including invasive fungal disease. Reduction in anthracycline exposure might shorten duration or depth of neutropenia or reduce mucosal injury, thereby lowering fungal risk. The trial’s ARSI data showing fewer invasive fungal infections in the omission arm are consistent with that mechanistic hypothesis, though the trial was not primarily designed to define mechanistic mediators.
Long‑term cardiotoxicity: the most compelling rationale for anthracycline reduction is reduced late cardiac morbidity. While the AIEOP‑BFM 2009 substudy demonstrates preserved oncologic efficacy and less acute infectious toxicity, it does not provide mature long‑term cardiac outcomes yet. The cardiotoxicity of anthracyclines is cumulative and can present years after exposure; therefore, long‑term follow‑up with serial echocardiography, strain imaging, biomarkers, and clinical surveillance will be necessary to show whether the modest reduction in total daunorubicin exposure from omitting two induction doses yields measurable reductions in late cardiac events.
Applicability and generalizability: Importantly, these findings apply to a very specific low‑risk population: non–high‑risk B‑ALL with favorable biology or rapid early response. They should not be generalized to higher‑risk disease, T‑cell ALL, infants, or patients with adverse biology. The trial’s careful risk‑stratified design demonstrates how response‑adapted therapy can safely permit de‑escalation in children with excellent early prognostic signals.
Potential guideline impact: given the trial size, quality, and clear noninferior outcomes, these data have the potential to influence induction protocols in centers that adopt AIEOP‑BFM strategies or similar risk‑adapted regimens. However, guideline bodies will likely await longer cardiac outcome data, confirmatory subgroup analyses, and integration with other late‑effect mitigation strategies before recommending widespread practice change.
Limitations
– The trial reports medium‑term (5‑year) EFS and OS; long‑term endpoints, particularly anthracycline‑related cardiotoxicity and late non‑malignant morbidity, are not yet mature and are critical for fully assessing the tradeoffs of anthracycline reduction.
– Findings are restricted to patients with favorable markers (ETV6::RUNX1 or rapid early responders). They cannot be extrapolated to higher‑risk groups where anthracyclines may have greater incremental benefit.
– Although invasive fungal infections were reduced, the mechanisms (reduced neutropenia duration, mucosal protection, or other immune effects) were not delineated by this report.
Clinical implications and recommendations
For clinicians treating pediatric B‑cell ALL, this trial supports a considered strategy of anthracycline de‑escalation in well‑selected, favorable‑risk patients. Practical takeaways include:
- Patients with ETV6::RUNX1 positivity or robust early blast clearance can be considered for induction regimens that omit two late daunorubicin doses without jeopardizing 5‑year EFS or OS.
- Centers adopting this approach should maintain rigorous early‑response assessment and risk stratification; this de‑escalation is not appropriate outside those defined groups.
- Continued long‑term surveillance for cardiotoxicity is essential because the reduction in early anthracycline exposure is modest and the benefit for late cardiac outcomes remains to be proven.
- Given the observed reduction in invasive fungal infections, clinicians may see fewer such complications, potentially translating into fewer treatment interruptions and resource use during induction.
Research priorities
Key next steps include extended follow‑up for cardiac outcomes among trial participants, echocardiographic and biomarker substudies to quantify myocardial injury, and meta‑analyses pooling trials that compare total anthracycline exposure in childhood ALL. Investigators should also explore mechanisms underlying the reduced invasive fungal infection rate and whether similar infectious benefits accrue with other anthracycline‑sparing strategies.
Conclusion
The AIEOP‑BFM ALL 2009 randomized substudy provides robust evidence that omission of two daunorubicin doses late during induction does not compromise 5‑year EFS or OS in a large cohort of children with favorable‑risk B‑cell ALL. It also demonstrates a clinically relevant reduction in invasive fungal infections. These results support response‑adapted anthracycline de‑escalation for defined low‑risk patients as part of a broader strategy to minimize late treatment morbidity while preserving excellent cure rates. Full appreciation of the impact on long‑term cardiac outcomes will require continued follow‑up.
Funding and trial registration
The trial report lists funding and group support as described in the primary publication. Trial registration: ClinicalTrials.gov NCT01117441.
References
1. Gottschalk H, Möricke A, Conter V, et al. Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. J Clin Oncol. 2025 Dec 10;43(35):3739-3749. doi: 10.1200/JCO-25-01357. Epub 2025 Nov 10. PMID: 41213101.
2. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015 Oct 15;373(16):1541-1552. doi:10.1056/NEJMra1400972.
3. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. Version 5.0 (2018). Available at: https://www.survivorshipguidelines.org/ (accessed 2025).
4. National Cancer Institute. PDQ® Childhood Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute. https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (accessed 2025).
